Publications by authors named "J N Butt"
Background: Bacteraemia and infective endocarditis (IE) are rare but severe complications of transcatheter aortic valve implantation (TAVI). Limited data exist on the incidence and microbiological profile of early bacteraemia in this population. This study aimed to evaluate the 6-month incidence of bacteraemia, IE and associated mortality following TAVI.
View Article and Find Full Text PDFBackground: In Australia, there are concerns that unrestricted junk food advertising during sports broadcasts increases short-term junk food consumption among viewers. Therefore, the present study aimed to estimate the impact of junk food and anti-junk food advertising on consumption inclinations.
Methods: We conducted a content analysis across a sample (N = 16) of Australian Football League (AFL) and National Rugby League (NRL) matches to determine the prevalence of junk food and anti-junk food advertising video clips.
Article Synopsis
- The Asia-Pacific region faces a significant challenge with obesity, which is linked to various health issues and rising medical costs; a hypothetical 10% weight loss could lead to significant savings over the next decade.
- Using an epidemiological-economic model, the study assessed current and future obesity-related health costs and problems in Australia, South Korea, Thailand, and India, revealing that costs could increase dramatically if no action is taken.
- A 10% weight reduction could save billions in medical expenses by 2032 while reducing the incidence of obesity-related comorbidities, highlighting the need for effective policies to support obesity management in the region.
Background: Obesity is associated with excessive adipocyte-derived aldosterone secretion, independent of the classical renin-angiotensin-aldosterone cascade, and mineralocorticoid receptor antagonists may be more effective in patients with heart failure (HF) and obesity.
Objectives: This study sought to examine the effects of the nonsteroidal mineralocorticoid receptor antagonist finerenone compared with placebo, according to body mass index (BMI) in FINEARTS-HF (FINerenone trial to investigate Efficacy and sAfety superioR to placebo in paTientS with Heart Failure).
Methods: A total of 6,001 patients with HF with NYHA functional class II, III, and IV, a left ventricular ejection fraction of ≥40%, evidence of structural heart disease, and elevated natriuretic peptide levels were randomized to finerenone or placebo.